Alaye siwaju sii ― Yoruba

Urticaria ti o wọpọ ṣafihan pẹlu awọn welt ti o ga ni yun. Nigba miiran o wa pẹlu wiwu ti awọn ara ti o wa ni abẹlẹ. Itọju akọkọ jẹ yiyọkuro awọn okunfa, ti o ba mọ. Oogun laini akọkọ pẹlu awọn antihistamines tuntun, eyiti o le ṣatunṣe si awọn iwọn giga ti o ba nilo. Awọn oogun miiran bi awọn antihistamines agbalagba, awọn blockers H2, awọn antagonists olugba leukotriene, awọn antihistamines ti o lagbara, ati awọn iṣẹ kukuru ti awọn corticosteroids le ṣe afikun bi atilẹyin afikun. Ni awọn ọran nibiti urticaria ti tẹsiwaju laisi awọn iwọn wọnyi, awọn alaisan le tọka si awọn alamọja fun awọn itọju afikun bii omalizumab tabi cyclosporine.
Urticaria commonly presents with intensely itchy raised welts. It is sometimes accompanied by swelling of the underlying tissues. Treatment primarily involves avoiding triggers, if known. First-line medication includes newer antihistamines, which can be adjusted to higher doses if needed. Other medications like older antihistamines, H2 blockers, leukotriene receptor antagonists, stronger antihistamines, and short courses of corticosteroids can be added as extra support. In cases where urticaria persists despite these measures, patients might be referred to specialists for additional therapies such as omalizumab or cyclosporine.

Atunwo yii ṣe apejuwe awọn ilana titun fun atọju urticaria ati pe o funni ni oye titun ti awọn idi rẹ.
This review outlines the latest guidelines for treating urticaria and offers new understandings of its causes.

Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), Omalizumab, Ciclosporin, and short courses only of systemic corticosteroids